valproic acid has been researched along with Attention Deficit and Disruptive Behavior Disorders in 15 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Attention Deficit and Disruptive Behavior Disorders: Includes two similar disorders: oppositional defiant disorder and CONDUCT DISORDERS. Symptoms occurring in children with these disorders include: defiance of authority figures, angry outbursts, and other antisocial behaviors.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 6.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 2.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "We recruited forty participants with Oppositional Defiant Disorder or Conduct Disorder." | 2.75 | Divalproex sodium-ER in outpatients with disruptive behavior disorders: a three month open label study. ( Delizonna, L; Hall, R; Mora, L; Saxena, K; Steiner, H; Torres, A; Torres, E, 2010) |
| " Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks." | 2.74 | Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. ( Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009) |
| " The mechanism of this proposed interaction may involve drug-drug competition at the level of hepatic glucuronidation (conjugation), although shifts in protein binding cannot be ruled out." | 2.69 | Increased plasma valproate concentrations when coadministered with guanfacine. ( Ambrosini, PJ; Sheikh, RM, 1998) |
| "All patients met DSM-IV criteria for a disruptive behavior disorder (oppositional defiant disorder of conduct disorder) in addition to research criteria." | 1.32 | "Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder? ( Donovan, SJ; Jensen, PS; Klein, DF; Nunes, EV; Quitkin, FM; Ross, D; Stewart, JW, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cortese, S | 1 |
| Novins, DK | 1 |
| Blader, JC | 1 |
| Schooler, NR | 1 |
| Jensen, PS | 2 |
| Pliszka, SR | 1 |
| Kafantaris, V | 1 |
| Saxena, K | 3 |
| Mora, L | 1 |
| Torres, E | 1 |
| Hall, R | 1 |
| Delizonna, L | 1 |
| Torres, A | 1 |
| Steiner, H | 3 |
| Glauser, TA | 1 |
| Cnaan, A | 1 |
| Shinnar, S | 1 |
| Hirtz, DG | 1 |
| Dlugos, D | 1 |
| Masur, D | 1 |
| Clark, PO | 1 |
| Capparelli, EV | 1 |
| Adamson, PC | 1 |
| West, AE | 1 |
| Weinstein, SM | 1 |
| Celio, CI | 1 |
| Henry, D | 1 |
| Pavuluri, MN | 1 |
| Donovan, SJ | 2 |
| Nunes, EV | 2 |
| Stewart, JW | 2 |
| Ross, D | 1 |
| Quitkin, FM | 2 |
| Klein, DF | 2 |
| Henry, CA | 1 |
| Zamvil, LS | 1 |
| Lam, C | 1 |
| Rosenquist, KJ | 1 |
| Ghaemi, SN | 1 |
| Yehya, N | 1 |
| Saldarini, CT | 1 |
| Koski, ME | 1 |
| Davanzo, P | 1 |
| Rana, M | 1 |
| Khanzode, L | 1 |
| Karnik, N | 1 |
| Chang, K | 2 |
| Howe, M | 1 |
| Simeonova, D | 1 |
| Kelsberg, G | 1 |
| St Anna, L | 1 |
| Rulon, EA | 1 |
| Barzman, DH | 1 |
| DelBello, MP | 1 |
| Adler, CM | 1 |
| Stanford, KE | 1 |
| Strakowski, SM | 1 |
| Lawson, WB | 1 |
| Nanos, J | 1 |
| Ambrosini, PJ | 1 |
| Sheikh, RM | 1 |
| Parides, M | 1 |
| Daniel, W | 1 |
| Susser, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder[NCT00228046] | Phase 4 | 40 participants (Anticipated) | Interventional | 2004-01-31 | Completed | ||
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study[NCT00088452] | Phase 3 | 453 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 35 |
| Lamotrigine | 25 |
| Valproic Acid | 52 |
Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 70 |
| Lamotrigine | 31 |
| Valproic Acid | 64 |
Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 81 |
| Lamotrigine | 43 |
| Valproic Acid | 85 |
2 reviews available for valproic acid and Attention Deficit and Disruptive Behavior Disorders
| Article | Year |
|---|---|
Divalproex sodium in the treatment of pediatric psychiatric disorders.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autistic Diso | 2005 |
Clinical inquiries. What are effective treatments for oppositional defiant behaviors in adolescents?
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents; Antimanic Agents; Atomoxetine Hydro | 2006 |
10 trials available for valproic acid and Attention Deficit and Disruptive Behavior Disorders
| Article | Year |
|---|---|
Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Topics: Adolescent; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Atten | 2009 |
Divalproex sodium-ER in outpatients with disruptive behavior disorders: a three month open label study.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Child; Female; GABA Age | 2010 |
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Topics: Adolescent; Analysis of Variance; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorde | 2010 |
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2011 |
Long-term outcome with divalproex in children and adolescents with bipolar disorder.
Topics: Adolescent; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; | 2003 |
Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder.
Topics: Adolescent; Affect; Aggression; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorder | 2006 |
The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2006 |
Effects of divalproex on disruptive behavior of jail inmates.
Topics: Adult; Antimanic Agents; Attention Deficit and Disruptive Behavior Disorders; Humans; Male; Middle A | 2008 |
Increased plasma valproate concentrations when coadministered with guanfacine.
Topics: Adrenergic alpha-Agonists; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Att | 1998 |
Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.
Topics: Adolescent; Ambulatory Care; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; C | 2000 |
3 other studies available for valproic acid and Attention Deficit and Disruptive Behavior Disorders
| Article | Year |
|---|---|
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2021 |
"Outer-directed irritability": a distinct mood syndrome in explosive youth with a disruptive behavior disorder?
Topics: Adolescent; Adult; Age Factors; Aggression; Anticonvulsants; Attention Deficit and Disruptive Behavi | 2003 |
Valproate-induced hyperammonemic encephalopathy.
Topics: Aggression; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorders; Child; Diagnosis, | 2004 |